268 related articles for article (PubMed ID: 38477884)
21. Management practice and treatment outcomes of adult patients with Lupus Nephritis at the Renal Clinic of St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.
Hailu GT; Hussen SU; Getachew S; Berha AB
BMC Nephrol; 2022 Jun; 23(1):214. PubMed ID: 35715762
[TBL] [Abstract][Full Text] [Related]
22. Genetics of human lupus nephritis.
Iwamoto T; Niewold TB
Clin Immunol; 2017 Dec; 185():32-39. PubMed ID: 27693588
[TBL] [Abstract][Full Text] [Related]
23. Renal-infiltrating CD11c
Liao X; Ren J; Reihl A; Pirapakaran T; Sreekumar B; Cecere TE; Reilly CM; Luo XM
Clin Exp Immunol; 2017 Nov; 190(2):187-200. PubMed ID: 28722110
[TBL] [Abstract][Full Text] [Related]
24. Lupus nephritis: new progress in diagnosis and treatment.
Yu C; Li P; Dang X; Zhang X; Mao Y; Chen X
J Autoimmun; 2022 Oct; 132():102871. PubMed ID: 35999111
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics and long-term outcomes in patients with mixed Class III/IV + V and pure proliferative lupus nephritis: A single-center experience.
Ahn SS; Yoo J; Lee SW; Song JJ; Park YB; Jung SM
Lupus; 2022 Apr; 31(5):588-595. PubMed ID: 35316102
[TBL] [Abstract][Full Text] [Related]
26. Pim-1 as a Therapeutic Target in Lupus Nephritis.
Fu R; Xia Y; Li M; Mao R; Guo C; Zhou M; Tan H; Liu M; Wang S; Yang N; Zhao J
Arthritis Rheumatol; 2019 Aug; 71(8):1308-1318. PubMed ID: 30791224
[TBL] [Abstract][Full Text] [Related]
27. Risk and Factors associated with disease manifestations in systemic lupus erythematosus - lupus nephritis (RIFLE-LN): a ten-year risk prediction strategy derived from a cohort of 1652 patients.
Chan SCW; Wang YF; Yap DYH; Chan TM; Lau YL; Lee PPW; Lai WM; Ying SKY; Tse NKC; Leung AMH; Mok CC; Lee KL; Li TWL; Tsang HHL; Yeung WWY; Ho CTK; Wong RWS; Yang W; Lau CS; Li PH
Front Immunol; 2023; 14():1200732. PubMed ID: 37398664
[TBL] [Abstract][Full Text] [Related]
28. Unraveling the podocyte injury in lupus nephritis: Clinical and experimental approaches.
Dos Santos M; Poletti PT; Milhoransa P; Monticielo OA; Veronese FV
Semin Arthritis Rheum; 2017 Apr; 46(5):632-641. PubMed ID: 27839739
[TBL] [Abstract][Full Text] [Related]
29. Fisetin reduces the senescent tubular epithelial cell burden and also inhibits proliferative fibroblasts in murine lupus nephritis.
Ijima S; Saito Y; Nagaoka K; Yamamoto S; Sato T; Miura N; Iwamoto T; Miyajima M; Chikenji TS
Front Immunol; 2022; 13():960601. PubMed ID: 36466895
[TBL] [Abstract][Full Text] [Related]
30. The Role of NLRP3 Inflammasome in Lupus Nephritis.
Oliveira CB; Lima CAD; Vajgel G; Sandrin-Garcia P
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830358
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-32γ: Possible association with the activity and development of nephritis in patients with systemic lupus erythematosus.
Kwon OC; Ghang B; Lee EJ; Hong S; Lee CK; Yoo B; Kim S; Kim YG
Int J Rheum Dis; 2019 Jul; 22(7):1305-1311. PubMed ID: 30941928
[TBL] [Abstract][Full Text] [Related]
32. Rituximab in systemic lupus erythematosus and lupus nephritis.
Beckwith H; Lightstone L
Nephron Clin Pract; 2014; 128(3-4):250-4. PubMed ID: 25471633
[TBL] [Abstract][Full Text] [Related]
33. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.
Steiger S; Ehreiser L; Anders J; Anders HJ
Front Immunol; 2022; 13():999704. PubMed ID: 36211360
[TBL] [Abstract][Full Text] [Related]
34. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis.
Mohan C; Putterman C
Nat Rev Nephrol; 2015 Jun; 11(6):329-41. PubMed ID: 25825084
[TBL] [Abstract][Full Text] [Related]
35. Identification of potential biomarkers for systemic lupus erythematosus by integrated analysis of gene expression and methylation data.
Zhang W; Liang G; Zhou H; Zeng X; Zhang Z; Xu X; Lai K
Clin Rheumatol; 2023 May; 42(5):1423-1433. PubMed ID: 36595110
[TBL] [Abstract][Full Text] [Related]
36. Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis.
Rafael-Vidal C; Altabás I; Pérez N; Mourino Rodríguez C; Pego-Reigosa JM; Garcia S
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33514066
[TBL] [Abstract][Full Text] [Related]
37. Worse Renal Presentation and Prognosis in Initial-Onset Lupus Nephritis than Early-Onset Lupus Nephritis.
Kwon OC; Park JH; Lee SW; Song JJ; Park YB; Park MC
Yonsei Med J; 2020 Nov; 61(11):951-957. PubMed ID: 33107238
[TBL] [Abstract][Full Text] [Related]
38. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.
Yap DYH; Chan TM
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835612
[TBL] [Abstract][Full Text] [Related]
39. Validity of immunoglobulin-binding protein 1 as a biomarker for lupus nephritis.
Ebaid AM; Ezzeldin N; Abdelhady EI; Mohammed HA; Abdallah AL
Lupus; 2023 Jan; 32(1):101-110. PubMed ID: 36418233
[TBL] [Abstract][Full Text] [Related]
40. Urinary levels of sirtuin-1 associated with disease activity in lupus nephritis.
Olivares D; Perez-Hernandez J; Forner MJ; Perez-Soriano C; Tormos MC; Saez GT; Chaves FJ; Redon J; Cortes R
Clin Sci (Lond); 2018 Mar; 132(5):569-579. PubMed ID: 29440621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
